At ASCO 2026 in Chicago, Pedro Valencia, vice president of asset strategy leadership for oncology at AbbVie, joined ...

Moderna has moved a little closer to US approval of its new mRNA-based seasonal influenza vaccine, mFlusiva, after an FDA ...

As such, Google AI Overviews represent a major shift in search for the pharma industry, moving from traditional link-based ...

Biogen has dipped its toe into the M&A waters once again, agreeing to buy San Diego-based RayThera for up to $1 billion in ...

Details are starting to emerge of last week's cyberattack on Novo Nordisk, which now appears to have been a $25 million ...

The first generic alternative to Roche's oral drug for influenza, Xofluza, has been approved by the FDA and should be ...

Two AI large language models (LLMs) have shown they can match and even surpass doctors in virtual testing, although their ...

The FDA refused to accept uniQure's filing for AMT-130 last November, and earlier this year the Dutch biotech said it had ...

Sanofi's subcutaneous formulation of multiple myeloma drug Sarclisa has been approved in the UK, which will be the first market for the on-body injector (OBI) version of the drug.

Moderna is hoping to launch three new vaccines in the next couple of years – including a flu shot that will come in front of ...

Dr Cavey discusses the evolution of radiopharma, beyond the original “two pillars” of GEP-NETs and PSMA, including the move ...

This article was developed and funded by Gilead Sciences Ltd. For decades, the UK life sciences sector has been the jewel in ...